October 2010
Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10
The article reports on the approval of the antihyperuricemic drug Krystexxa, an enzyme that lowers uric acid levels which is used to treat gout in adults, manufactured by Savient Pharmaceuticals.


Related Articles

  • Savient for Sale, Ardea Bid Adds Dose: Gout on Move. Osborne, Randy // BioWorld Insight;5/17/2010, Vol. 18 Issue 20, p2 

    The article offers information on several companies that developed medicine for gout. It mentions that Savient Pharmaceuticals Inc. attempt to apply for biologics license application for Krystexxan, a drug to be tested to very symptomatic gout patients and announces that its company is for sale....

  • Savient Gout Drug Wins FDA OK; Firm for Sale. Young, Donna // BioWorld Today;9/16/2010, Vol. 21 Issue 179, p1 

    The article announces the approval given by the U.S. Food and Drug Administration (FDA) to Savient Pharmaceuticals Inc. for its Krystexxa pegylated uric acid specific enzyme for chronic refractory gout. According to Savient President Paul Hamelin, the approval demonstrated what a small...

  • Bumpy launch for Savient's new gout drug. Iskowitz, Marc // Medical Marketing & Media;Feb2011, Vol. 46 Issue 2, p10 

    The article focuses on the problems reported by Savient Pharmaceuticals Inc. during the preparations for the launch of its gout drug Krystexxa.

  • Savient Prices Offering: $53M on Gout Route to Profitability. Osborne, Randy // BioWorld Today;10/12/2009, Vol. 20 Issue 196, p1 

    The article looks at the launch of the gout drug Krystexxa (pegloticase) by Savient Pharmaceuticals Inc. It states that the drug was priced by Savient at 13.29 U.S. dollars per share and expected to sell 4.3 million shares. It states that the company's previous cutbacks and 52.9 million U.S....

  • Krystexxa for chronic gout.  // Nurse Practitioners Prescribing Reference;Winter2010/2011, Vol. 17 Issue 4, pA.19 

    The article reports on the approval of Krystexxa, a pegloticase injection from Savient Pharmaceuticals Inc. that was made up of a PEGylated uric acid specific enzyme for the treatment of chronic gout among adult patients under refractory and conventional therapies.

  • Pharma Developments.  // Cardiovascular Devices & Drugs;Dec2008, Vol. 14 Issue 12, p18 

    The article focuses on a research note by Cowen & Co. analyst Rachel McMinn which indicated that Savient Pharmaceuticals intended to file a biologic license agreement for Puricase by the end of December 2008. The company claimed in late October 2008 that there is no causality between cardiac...

  • FDA Review of Gout Drug Sends Savient Stock Soaring. Young, Donna // BioWorld Today;6/15/2009, Vol. 20 Issue 113, p1 

    The article reports on a 56 percent increase in the shares of Savient Pharmaceuticals Inc. on June 12, 2009. The company's shares increased after the U.S. Food and Drug Administration (FDA) announced the effectiveness of its gout treatment Krystexxa. The company is pursuing the approval of the...

  • DATAMONITOR: Savient Pharmaceuticals Inc.  // Savient Pharmaceuticals Inc. SWOT Analysis;Jun2010, p1 

    A company profile of Savient Pharmaceuticals Inc., which is a specialty biopharmaceutical company engaged in developing Krystexxa (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy, is presented. An overview of the company is given, along with key...

  • In the News.  // njbiz;12/13/2004, Vol. 17 Issue 50, p2 

    Presents updates on the business sector in New Jersey as of December 2004. Efforts of acting governor Richard J. Codey and social service groups to increase the state's minimum wage; Role of the conversion of Horizon Blue Cross Blue Shield of New Jersey from a nonprofit health insurer to a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics